Beta Bionics, Inc. (BBNX) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Beta Bionics reported revenue of $100.3M, up 53.9% from $65.1M the year before. Net income was -$73.2M (a -73.0% net margin), or -$1.81 per diluted share. Gross margin was 55.4% and operating margin was -71.5%. Operating activities generated -$50.9M of cash, leaving -$56.2M of free cash flow. At fiscal year end, Beta Bionics held $328.7M in total assets against $41.1M in total liabilities, including $31.6M of cash and equivalents.
Open the full interactive Beta Bionics financials → Quarterly statements, key ratios, valuation history and price charts.
Beta Bionics Key Stats
| Share Price | $17.69 |
|---|---|
| Market Cap | $788.0M |
| Revenue YoY Growth | +53.9% |
| 52-Week Range | $8.86 – $31.99 |
| Shares Outstanding | 44.5 million (basic, 2026 Q2) |
Beta Bionics Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $65.1M | $100.3M |
| Cost of Goods Sold | $29.2M | $44.7M |
| Gross Profit | $35.9M | $55.5M |
| Operating Income | -$45.3M | -$71.7M |
| Pre-Tax Income | -$54.8M | -$73.2M |
| Income Tax | — | $0 |
| Net Income | -$54.8M | -$73.2M |
| Diluted EPS | -$8.60 | -$1.81 |
Beta Bionics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $27.3M | $32.1M | $27.6M | $32.0M |
| Net Income | -$14.2M | -$13.5M | -$21.9M | -$23.4M |
| Diluted EPS | -$0.33 | -$0.33 | -$0.49 | -$0.53 |
Beta Bionics Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $30.4M | $31.6M |
| Current Assets | $132.9M | $267.9M |
| Total Assets | $149.6M | $328.7M |
| Current Liabilities | $21.1M | $30.9M |
| Total Long-Term Debt | $100,000 | $100,000 |
| Total Liabilities | $73.6M | $41.1M |
| Shareholders' Equity | -$245.4M | $287.6M |
Beta Bionics Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$48.3M | -$50.9M |
| Cash From Investing | -$3.5M | -$162.8M |
| Cash From Financing | $55.6M | $214.9M |
| Free Cash Flow | -$51.7M | -$56.2M |
Figures from Beta Bionics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Beta Bionics financials page for every line item.
Beta Bionics Company Profile
| Ticker | BBNX |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Irvine, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001674632 |
Frequently Asked Questions
What was Beta Bionics' revenue in fiscal 2025?
Beta Bionics (BBNX) reported revenue of $100.3M for fiscal 2025.
What was Beta Bionics' net income in fiscal 2025?
Beta Bionics reported net income of -$73.2M for fiscal 2025.
What was Beta Bionics' earnings per share (EPS) in fiscal 2025?
Beta Bionics' diluted EPS was -$1.81 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Beta Bionics generate in fiscal 2025?
Beta Bionics generated -$56.2M of free cash flow in fiscal 2025.
What was Beta Bionics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Beta Bionics reported revenue of $32.0M.
How much debt does Beta Bionics have?
Beta Bionics reported $100,000 of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Beta Bionics are outstanding?
Beta Bionics reported a weighted average of 44.5 million basic shares outstanding in 2026 Q2.
What is Beta Bionics' market cap?
Based on its latest closing price, Beta Bionics (BBNX) has a market capitalization of about $788.0M.
When does Beta Bionics' fiscal year end?
Beta Bionics' fiscal year end, as registered with the SEC, is December 31.
Where is Beta Bionics headquartered?
Beta Bionics lists its business address in Irvine, California in its SEC filings.